Sidoti Predicts Kamada’s Q1 Earnings (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA) – Equities researchers at Sidoti issued their Q1 2028 earnings per share estimates for Kamada in a research report issued on Tuesday, August 18th. Sidoti analyst J. Sidoti anticipates that the biotechnology company will earn $0.13 per share for the quarter. The consensus estimate for Kamada’s current full-year earnings is $0.49 per share. Sidoti also issued estimates for Kamada’s Q2 2028 earnings at $0.15 EPS.

A number of other equities analysts have also commented on the stock. Wall Street Zen upgraded shares of Kamada from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings downgraded Kamada from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 25th. Benchmark reaffirmed a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. Finally, William Blair set a $15.00 price objective on Kamada in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $13.00.

Kamada Stock Performance

KMDA opened at $7.89 on Wednesday. The firm has a market cap of $453.71 million, a price-to-earnings ratio of 20.76, a PEG ratio of 0.67 and a beta of 0.86. The firm’s 50-day simple moving average is $7.25 and its 200-day simple moving average is $7.94. Kamada has a twelve month low of $6.50 and a twelve month high of $9.35.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. Kamada had a return on equity of 8.37% and a net margin of 11.60%.The company had revenue of $54.92 million during the quarter, compared to analysts’ expectations of $50.84 million.

Kamada Cuts Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, September 17th. Stockholders of record on Thursday, August 27th will be paid a dividend of $0.17 per share. This represents a dividend yield of 219.0%. The ex-dividend date of this dividend is Thursday, August 27th. Kamada’s dividend payout ratio is 47.37%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Barclays PLC raised its stake in shares of Kamada by 417.1% during the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock worth $34,000 after buying an additional 3,862 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Kamada during the 4th quarter valued at $66,000. XTX Topco Ltd acquired a new position in shares of Kamada in the 4th quarter valued at $103,000. SIH Partners LLLP acquired a new position in shares of Kamada in the 4th quarter valued at $134,000. Finally, Quadrature Capital Ltd boosted its position in shares of Kamada by 53.5% in the 4th quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 7,627 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.